U
ncontrolled acromegaly is associated with significant morbidity and an increased mortality rate compared with the general population (1) . Analysis of the key determinants of mortality in acromegaly indicates that approximately 60% of patients die from cardiovascular causes, 25% from respiratory disease, and 15% from malignancy (1) (2) (3) (4) . The extent to which acromegaly raises the risk of cancer in affected subjects remains controversial, with several studies suggesting a modest increase, although this has not been a universal finding (2, (5) (6) (7) . Those cancers with a reported higher prevalence include colon, breast, and possibly thyroid, with colon carcinoma the most extensively studied (2, (5) (6) (7) (8) . Several groups have reported increased rates of both colonic tubulovillous adenoma and overt adenocarcinoma (2, 8 -10) , and although this has been contested by some workers (11) , many endocrinologists now offer colonoscopic surveillance to patients with acromegaly (5) .
Gallbladder polyp (GBP) prevalence varies from approximately 5% in Caucasians up to 10% in Chinese populations (12) (13) (14) . Although gallbladder carcinoma (GBC) is relatively rare, it is the most common biliary tract malignancy (15) . Fewer than 5% of patients with GBC survive 5 yr, so early detection and treatment are essential (12, 15) . Because GBP are commonly identified during biliary ultrasound, the challenge is to discriminate those that carry a risk of malignant transformation, and in whom cholecystectomy is indicated, from benign lesions (e.g. cholesterol or hyperplastic polyps). Recognized risk factors for GBC in ultrasound-detected GBP include age older than 50 yr, Indian ethnicity, the presence of gallstones, marked gallbladder wall thickening, solitary lesions, and GBP size greater than 10 mm (12) . However, recent studies suggest that even smaller polyps (Ͼ6 mm diameter) can harbor a potential for malignant transformation (15) . In light of the poor prognosis of GBC and the relative safety of laparoscopic surgery, many hepatobiliary centers now advise cholecystectomy for subjects in higher risk groups (13) .
Little is known about GBP in acromegaly. Although earlier studies did not report an increased prevalence (16, 17) , a recent retrospective case series found GBP in 11 of 77 patients who had undergone abdominal imaging [ultrasound (US) or computed tomography] (14.3%) from a total cohort of 140 patients, but the background rate in a contemporaneous nonacromegalic population was not reported, making it difficult to determine the degree to which the acromegaly per se contributed to this apparent increased prevalence of GBP (8) . We therefore sought to determine the prevalence of GBP in patients with newly diagnosed acromegaly attending our regional pituitary endocrine service and to compare this with the background prevalence in patients without known acromegaly attending our radiology department for biliary US, in a retrospective casecohort study. As a secondary objective, we examined the associations of age, gender, and mean GH and IGF-I levels with GBP in the patients with acromegaly.
Patients and Methods

Patients
Thirty-one consecutive, newly diagnosed patients with acromegaly (14 females, 17 males) were referred to our center for endocrine assessment and pituitary surgery between January 2004 and December 2008. The mean age at referral was 54.7 yr (range 27-76 yr). Acromegaly was diagnosed on the basis of clinical features, failure to suppress serum GH concentrations to less than 0.8 g/liter after a 75-g oral glucose load, and elevated fasting IGF-I (above the age and sex matched reference range). Mean GH levels during a day curve were determined from 10 samples collected at hourly intervals between 0800 and 1700 h.
The standard approach to treating acromegaly in our center includes a course of somatostatin analog therapy before surgery. Because the development of gallstones is a recognized complication of somatostatin therapy, all patients underwent biliary US scanning (USS) before commencing treatment.
Biliary ultrasonography
USS was performed by consultant radiologists, senior residents, or senior technicians with expertise in ultrasonography. The reports and images of all 31 patients with acromegaly were reviewed retrospectively. No specific request to identify or exclude GBP was made before scanning. However, all GBP identified on abdominal/biliary ultrasound are routinely reported in our center. These are defined as fixed echogenic, usually spherical, filling defects protruding into the lumen of the gallbladder, which do not move with changes in posture. They may occasionally arise from a short stalk but are usually sessile. The lesions do not produce an acoustic shadow, in contrast to an adherent gallstone.
The prevalence of GBP in patients aged 20 -80 yr, who were not known to have acromegaly, and who underwent abdominal/ biliary USS in our radiology department during the same time period, was also determined retrospectively. During this interval a total of 20,032 examinations were performed. All of these reports were retrieved from our radiology department database and, after excluding repeat scans and those from patients with previous cholecystectomy, 13,234 cases aged 20 -80 yr were identified for inclusion in the study [comprising 7605 women (57.5%) and 5629 men (42.5%)]. Twenty-two of these subjects (10 males and 12 females) were known to us with pituitary tumors other than acromegaly. US images from a subgroup of controls (n ϭ 217) and patients with acromegaly (n ϭ 10) were also reassessed by an independent radiologist in a blinded manner to confirm accuracy of original reporting and for the purposes of a case-control analysis (see Supplementary Methods, published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Biochemical measurements
All basal blood samples were collected after overnight fasting. Serum GH and IGF-I were measured using solid-phase assays (see Supplementary Methods for further details) calibrated to international standard 98/574 and international standard 87/ 518, respectively. IGF-I levels are shown as ϫ upper limit of normal (ULN).
Statistical analysis
The analysis of differences in prevalence of GBP between patients with acromegaly and control subjects was conducted using the Fisher's exact test, whereas a Mantel-Haenszel test was used to test for odds ratio unity. In addition, a Monte Carlo-type simulation was undertaken (see Supplementary Methods for details). The influence of GH and IGF-I on GBP prevalence was assessed using a general linear models ANOVA with sex as a fixed factor and the presence (Ն1) or absence of GBP as a random factor. Due to the highly skewed nature of the data, GH and IGF-I were rank transformed before statistical analysis. For all analyses the threshold for statistical significance was set at P Ͻ 0.05.
The study was approved by the Caldicott guardian in our institution.
Results
One subject with acromegaly had previously undergone cholecystectomy for gallstones. His operative pathology report described multiple calculi but no GBP. Nine of the remaining 30 patients had GBP identified on ultrasound (Table 1 and Supplemental Fig. 1) , giving a point prevalence of 29.03%. In contrast, GBP were found in only 4.62% of control subjects (611 of 13,234 scans; P ϭ 0.000008). Of note, none of the 22 subjects in the control group with pituitary tumors other than acromegaly had GBP. The relative risk of GBP in the acromegaly group compared with controls was 6.29 (95% confidence interval 3.61-10.96). The calculated odds ratio was 8.45 (95% confidence interval 3.88 -18.43, Mantel-Haenszel test, P ϭ 0.00000008).
In the case-control analysis, only two of the 217 controls were found to have GBP (both correctly identified in the original reports); one of these individuals was a control for an acromegalic patient with GBP, whereas the second was a control for an acromegalic patient without GBP (case-control odds ratio 62.00, 95% confidence interval 21.64 -177.62, Cochran Mantel-Haenszel test, P Ͻ 0.000001).
By Monte Carlo simulation analysis (1 million iterations), the frequency of finding at least nine patients with GBP in a group of 31 individuals repeatedly selected at random from a total population of 13,265 (containing 620 individuals with GBP) was 0.000027. This probability calculated by the simulation is therefore consistent with the value calculated by the Fisher's exact test.
In the acromegaly cohort, six patients had solitary polyps, no patient had more than three polyps, and polyp size ranged from 2.0 to 5.0 mm (findings were confirmed in the blinded reanalysis of images). Eight of nine patients with acromegaly and GBP were aged older than 50 yr (Fig. 1A) , and GBP were found more frequently in female subjects (six of 14 patients) than males (three of 17 patients). We were unable to detect a relationship between duration of Thin  0  23  57  M  0  Thin  0  24  55  F  0  Thin  0  25  44  M  0  Thin  0  26  50  M  0  Thin  0  27  58  M  0  Thin  0  28  41  F  0  Thin  0  29  49  F  Multiple  Thickened  0  30  28  F  0  Thin  2  3.5  31  74  M  0  Thin  1  3 GB, Gallbladder; M, male; F, female. a Previous cholecystectomy; subjects 21 and 29 also exhibited typical radiological features of adenomyomatosis.
symptoms of acromegaly before diagnosis and the presence of GBP. However, GH levels in acromegalic patients with GBP were significantly higher than in those without GBP: median GH 30.8 g/liter [interquartile range 10.9 -39.1) vs. 8.2 g/liter (6.0 -16.0), P ϭ 0.014, respectively (Fig. 1B) ]. There was no significant difference in GH concentrations between male and females and no difference between the two genders with respect to those with or (Fig. 1C) ].
Discussion
These findings show for the first time that compared with a large contemporary control population, there is a significantly higher prevalence of GBP in patients with newly diagnosed acromegaly. This is consistent with a previous report suggesting an excess of GBP in a cohort of Japanese patients with acromegaly (8) . However, no control data were provided in this earlier study to allow determination of a local prevalence rate for the background population, and abdominal imaging data were available in only half of the acromegalic cohort (8) . Our data confirm that acromegaly predisposes to radiologically detectable GBP. Earlier studies examining gallstone prevalence and gallbladder motility in untreated acromegaly did not observe a higher rate of GBP (16, 17) . However, the greater resolution of modern ultrasonography may partly explain the increased detection of small (2-5 mm) GBP in our cohort. Both dysplasia, predisposing to the development of carcinoma in situ, and the so-called adenoma-carcinoma sequence have been implicated in the pathogenesis of GBC (15, 18, 19) . However, whether there is an increased risk of GBC in patients with acromegaly remains to be determined. To date, there are no reports of an increased rate of GBC in acromegaly, but the finding that most patients with GBP in our study were older than 50 yr of age and had solitary polyps raises concern and suggests that further studies should be undertaken to address this important issue.
It also remains unclear as to how acromegaly might predispose to GBP formation. Both chronically elevated GH and IGF-I levels have been implicated in tumorigenesis in a variety of tissues (5, 7). In the colon, IGF-I exerts antiapoptotic effects and has been shown to promote proliferation of the epithelium (especially of the crypt cells), which is an important first step in the pathway to adenoma formation (5, 20, 21) . It is possible that a similar pathogenic mechanism may be at play in the gallbladder. Interestingly, we observed higher GH levels in patients with GBP than those without, although IGF-I levels did not differ significantly (Fig. 1, B and C) . However, the numbers reported here are relatively small, and again further studies in larger cohorts of patients would be required to clarify whether there is indeed a link between ambient GH/IGF-I levels and the propensity to develop GBP.
